Novel Immunotoxin and IGF Therapy for Strabismus

新型免疫毒素和 IGF 治疗斜视

• 批准号: 8511649
• 负责人: LINDA K. MCLOON
• 金额: $ 53.04万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8511649
• 关键词: Adult; Aftercare; Amblyopia; Antibodies; BMP4; Blindness; Brain; Brain-Derived Neurotrophic Factor; Calibration; Child; Childhood; Data; Development; Diagnosis; Disease; Early treatment; Etiology; Excision; Eye; Eye Movements; Failure; Generations; Goals; Growth; Growth Factor; Growth Factor Receptors; Human; IGF1 gene; Immunotoxins; Individual; Infant; Injury; Insulin-Like Growth Factor I; Knowledge; Lead; Maintenance; Methods; Modeling; Molecular; Monkeys; Motor; Motor Neurons; Movement; Muscle; Nerve; Neuromuscular Junction; Neuronal Plasticity; Neurons; Operative Surgical Procedures; Oryctolagus cuniculus; Pattern; Physiological; Plastics; Positioning Attribute; Property; Sensory; Signal Transduction; Strabismus; Structure; Synapses; Synaptic plasticity; System; Testing; Translating; United States; Vision; alternative treatment; axon growth; base; critical period; density; gaze; improved; infancy; mind control; motor control; nerve supply; nonhuman primate; novel; oculomotor; orbit muscle; prevent; receptor expression; satellite cell

DESCRIPTION (provided by applicant): Our studies are directed at advancing treatments to cure infantile and acquired strabismus. At least 3% of the children born in the U.S. are diagnosed with strabismus each year. Early treatment of strabismus can prevent loss of visual function, but strabismus management remains challenging. This is partly because we lack a definitive understanding of its etiology. Our studies will fill this gap in knowledge and lead to improved therapies for strabismus. Eye misalignment in some cases is likely due to improper calibration of the tonic innervation of individual extraocular muscles (EOM) or specific muscle compartments. Acquired strabismus may follow injury of EOM or their innervation. Ultimately, eye alignment, gaze-holding and eye movements all depend on the quality of ocular motor innervation supplied to the EOM. Our studies will determine how current surgical methods and novel application of growth factors alter oculomotor neuronal properties associated with eye alignment. Our long term goal is to develop pharmacologic therapies to modulate force in an "underacting" or "overacting" EOM by changing intrinsic neuronal firing properties and innervational density and modulating perineuronal nets on the motor neurons that innervate the EOM to allow for synaptic plasticity and motor fusion. We will test these strategies in a non-human primate model of sensory-induced strabismus. We also hope to prevent maladaptations that occur after normal human strabismus surgery in order to reduce surgical failure rate. We have 5 specific aims: I. What are the molecular signals that influence the growth of axons and maintain the innervational pattern of the extraocular muscles? We will analyze patterns of growth factor and receptor expression in rabbit EOM, followed by use of exogenously added growth factors or antibodies to modulate the innervational pattern and density. II. Can EOM innervation be manipulated so that maladaptations at the muscle level that occur after surgical recession and/or resection are prevented? We will manipulate nerve growth in EOM by either promoting or preventing proliferation of satellite cells and/or nerve sprouting and neuromuscular junction formation. III. Can we modulate the perineuronal nets around mature motor neurons, and does this result in altered synaptic connections after sustained growth factor treatments? We will define perineuronal net structure and determine efficacy of sustained release BDNF, IGF1, and BMP4 to modulate perineuronal nets, and determine if it will restore motor neuron synaptic plasticity. IV. How do our proven growth factors alter oculomotor neuronal firing properties in the ocular motor system of normal non- human primates? We will analyze neuronal firing rates after treatments we pioneered, IGF-1 and BMP4, which increase or decrease force generation and muscle size. V. We hypothesize that growth factors can effectively treat strabismus. We will use our established methods to produce sensory-induced strabismus in infant monkeys, and then evaluate novel treatments employing growth factor treatments to correct eye misalignment.

描述（由申请人提供）：我们的研究是针对先进的治疗，以治愈婴儿和后天性斜视。每年至少有3%在美国出生的儿童被诊断为斜视。斜视的早期治疗可以防止视功能的丧失，但斜视的管理仍然具有挑战性。部分原因是我们对其病因缺乏明确的了解。我们的研究将填补这一知识空白，并导致斜视治疗的改进。在某些情况下，眼睛错位可能是由于个别眼外肌（EOM）或特定肌肉室的紧张性神经支配的不正确校准。眼外肌或其神经支配受损可导致获得性斜视。最终，眼睛对齐，凝视和眼球运动都取决于眼外肌提供的眼运动神经支配的质量。我们的研究将确定当前的手术方法和生长因子的新应用如何改变与眼睛对齐相关的眼神经元特性。我们的长期目标是开发药理学疗法，通过改变内在神经元放电特性和神经支配密度以及调节支配EOM的运动神经元上的神经元束膜网络以允许突触可塑性和运动融合来调节“作用不足”或“作用过度”EOM中的力。我们将在非人类灵长类动物的感觉诱发性斜视模型中测试这些策略。我们也希望能预防正常人斜视手术后发生的适应不良，以减少手术失败率。我们有五个具体目标：一。影响轴突生长和维持眼外肌神经支配模式的分子信号是什么？我们将分析兔眼外肌中生长因子和受体表达的模式，然后使用外源性添加的生长因子或抗体来调节神经支配模式和密度。二.眼外肌的神经支配是否可以被控制，从而防止手术后发生的肌肉水平的适应不良？我们将通过促进或阻止卫星细胞的增殖和/或神经发芽和神经肌肉接头的形成来操纵眼外肌中的神经生长。三.我们能否调节成熟运动神经元周围的神经元膜网络，以及这是否会导致持续生长因子治疗后突触连接的改变？我们将定义神经元周围的网络结构，并确定持续释放BDNF，IGF 1和BMP 4调节神经元周围网络的功效，并确定它是否会恢复运动神经元突触可塑性。四.我们已证实的生长因子如何改变正常非人灵长类动物眼运动系统中眼神经元的放电特性？我们将分析我们开创的治疗后的神经元放电率，IGF-1和BMP 4，增加或减少力量产生和肌肉大小。我们假设生长因子可以有效治疗斜视。我们将使用我们建立的方法在幼猴中产生感觉诱导性斜视，然后评估采用生长因子治疗来纠正眼睛错位的新治疗方法。